Stryker Stock To Go Ex-dividend Tomorrow (SYK)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- The ex-dividend date for Stryker Corporation (NYSE: SYK) is tomorrow, June 26, 2013. Owners of shares as of market close today will be eligible for a dividend of 27 cents per share. At a price of $65.25 as of 9:30 a.m. ET, the dividend yield is 1.6%.

The average volume for Stryker has been 1.4 million shares per day over the past 30 days. Stryker has a market cap of $24.8 billion and is part of the health care sector and health services industry. Shares are up 18.1% year to date as of the close of trading on Monday.

Stryker Corporation, a medical technology company, provides reconstructive, medical and surgical, and neurotechnology and spine products for doctors, hospitals, and other healthcare facilities. The company has a P/E ratio of 20.1, above the S&P 500 P/E ratio of 17.7.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

TheStreet Ratings rates Stryker as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. You can view the full Stryker Ratings Report.

See our dividend calendar or top-yielding stocks list.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more..
null

If you liked this article you might like

These Stocks Are Ready to Reverse Course

Don't Get Out of Joint

Zimmer Biomet: Cramer's Top Takeaways

Market Stands at a Make-Or-Break Level: Cramer's 'Mad Money' Recap (Monday 7/17/17)

Analyst Says Rival Bidder Could Emerge for Novadaq After Stryker Deal